Finance Review Daily is tracking this developing story; additional confirmed specifics had not been verified at the time of publication.
Novartis discontinues development of experimental ALS drug VHB937 (lifonebart) after mid-stage trial failure.
Finance Review Daily is tracking this development following a report from the original source. Additional confirmed specifics had not been verified at the time of publication.
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
